I looked at the borrow availability for SAVA today. It showed 1K available with a 169% interest rate.

I'm pretty happy with Anavex share price today. Down less than 1% in a very ugly market. XBI -2.72%

Not sure why you feel that way. Owning Anavex over 7 years has allowed me to build a substantial position at a cost basis that I could not otherwise have.

SAVA is getting manipulated just like AVXL was when it ran up to $31.

You keep using that word "if". Sorry, but that isn't going to cut it.

There are blood tests that are coming online that look at phosphorylated Tau that seems to have very good diagnostic reliability for prodromal AD.

That seems to be the best one I have run across lately for early diagnosis.

Alas. There used to be a platform called Island where orders were matched with no MM in between. It was very popular with day traders and others. It became very successful, so it was bought out and made to go away.
AFAIK there is nothing like that for retail anymore.

We will have to wait and see exactly what course management chooses to take.

There is more than one path forward.

Zero as far as I know.

The SAEs were 16.7% (pooled) for the treatment group and 10.1% for the placebo group. That indicates a low rate of SAEs. Neither group had a description of what the SAEs were.

What were listed were classified as TEAEs. Treatment Emergent Adverse Events. That category apparently includes the serious TEAEs.

Here's how Dr. Sabbagh characterized the TEAE and AEs.

One aspect of this discussion that has been overlooked is the percentage of people that have tolerability issues or failure of efficacy what the approved CNS drugs. And that is after they are approved.

We have already discussed the strict inclusion criteria in the mab trials as opposed to the much more inclusive criteria for the 2-73 trials.

That is a comparison that will provide some context to this discussion.

I must disagree with your logic.

Sawston is a commercial production facility. I am unaware of any requirement for FDA approval that discusses the amount of commercial production volume required for approval.

Sure Sawston is not adding the tiny high purity clean rooms. I agree that the company is focused on the EDEN production method. It looks like the UK demand will consume all of the existing Sawston production capacity.

Maybe NWBO will not file with the FDA until the EDEN technology is ready for inspection. That seems to be an avoidable delay in the FDA approval process.
The company can file with the FDA based on the SAWSTON facility and get the approval timeline started. If the FDA NDA is approved prior EDEN being ready that is not a problem. The company doesn't have to accept requests for treatment, but will have approval in hand. When Sawston has EDEN ready the company can file for approval of the EDEN process with the UK and the FDA simultaniously. At that point it can begin to service the US demand.

I agree that making the treatment available in the US will most likely require the EDEN process to be able to service the demand.

But do sugar pills reduce brain shrinkage?

More information was shown in other presentation slides. Some complain about slides being too dense in information and now the complaint is the slide doesn't provide all the information. Can't win.

.

Thanks. I didn't notice that in the PR.

So that hasn't been tested in a trial, but has been utilized in the compassionate use program.

I'm guessing they will be doing that in as many future trials as they can.

Do you have any support for that statement?

As I understood what was said was that in future trials or in prescribing it would be taken at bed time.

That sounds like BS to me. Schwab has no problems with Anavex options.

Covered calls for the risk averse.

I agree. I check the posts under review and very seldom see anything there. Most people don't request a review.

According to the chart is was lower than placebo. About half.

I exercised my options and then sold the shares. Up 66% on that trade. Not willing to see what the rest of the week brings.

None of the mitigation procedures that have been suggested were utilized in that trial. No dosing at bedtime, no slower titrations.

We don't know how effective those will be. They do seem like reasonable things to try going forward.

What, you don't like your assumptions challenged?

Nonsense.

You can appeal any deleted post to admin. If too many posts deleted by a mod are restored the mod will be removed. I have seen that happen multiple times. I also got a caution from admin myself a long time ago.

Last time I checked Q4 is in the 2nd half.

Gosh, Who knew that things could change since the P2a trial?

Sheesh.

You are making some pretty strong assertions based on little information.

You have no idea exactly what is meant by the word dizziness in this case. Is it dizziness when standing? Is it dizziness when turning the head? Is it dizziness like when you have had way too much to drink and the room is spinning? You have no idea how lying down affects the dizziness experienced by those people. You don't know how the experienced dizziness affects the ability to go to sleep. It might make it easier or it might make it more difficult. You have no idea.

The one thing I will agree with is that lying down lessens fall risk.

They did that and it was a big mess. That is why the rules have changed back to being more restrictive.

I wish there was some way to vote some posters off the island. However I can't think of a way to do that in a way that wouldn't result in cliques forming just to get people off a board and control the narrative.

There are some people that just like throwing grenades and watching things burn. Ignore is not a great solution.

It is an article published on Seeking Alpha. The author is trying to create a following and the resulting income.

Anavex just had a very big up day and that creates interest in it. By producing an article about Anavex she is capitalizing on the new interest and hopefully generating new followers.

Motley Fool does a similar thing for similar reasons.

Ummm. I think that Anavex management has something to say about that.

Approval for centralized procedure is a mandatory requirement for CNS drugs in the EU.

That is a required first step in the approval process.

My cut and paste didn't bring over the red font.

It also can not become effective until completion, which was the point of my quoting the S-3.

From the new S3.

Picked up 6 more Fri $6 options

I just bought 4 Friday $6 options. Taking a swing at it.

Knowing that the S3 was a replacement for the existing S3 makes things a bit more attractive.

Most of the narrative today has been wrong, including some of mine.

You are close to my thinking. The issue isn't the number of shares so much as it is the total value of those shares.

As you say, the short term effect can be negative depending on what the company says it will use the money for.

As for your smaller ownership percentage argument, that depends on the size of the pie. A smaller slice of a larger pie can be more pie.

1 share at $5 = $5
.75 shares at $10 = $7.50

Anavex filed a shelf offering. Not a single share has been sold and the share price is getting pounded today. This S3 gave the shorts something to work with along with the mice PR, and they are making the most of it.

That is not quite true. It depends on what the company does with the money it raises by selling stock.

If the company uses the money raised to increase the value of the company then there is no dilution.
In the case of Anavex, if that money results in an approval on multiple indications, the increase in share price will more than make up for the increased number of shares outstanding.

If the money raised does not result in an increase in SP commensurate with the increase in shares, then it is dilution.

Mostly it was your rush to find a way to dis Missling and the company.

You have no idea what that shelf registration is for. There are many options and I suspect that is why this is being done, to provide options for the company.

Thanks WM. I didn't recall Missling saying that. So we have an approximate timeline with a little support.